Literature DB >> 19409040

Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.

M Jules Mattes1, Rosana B Michel, David M Goldenberg, Robert M Sharkey.   

Abstract

UNLABELLED: There are many reports that cross-linking antibodies (Abs) bound to the surface of B-lymphoma cells can induce apoptosis and/or cell death, especially with anti-CD20 Abs. This study was intended to extend our understanding of these effects. To determine if CD20 is a unique target in this respect, or whether Abs to other antigens would have similar effects, six Abs were tested, with and without cross-linking with a secondary Ab, on three target cell lines. We utilized assays that distinguish between apoptotic, dead, and viable cells. Two assays were used: Annexin V plus propidium iodide, and JC-1 plus SYTOX green (Molecular Probes, Eugene, OR). Most of the Abs tested induced a low level of apoptosis and cell death in Ramos cells, but not in the other two cell lines (Raji and RL). In general, the level of toxicity was correlated with the level of antigen expression, with Abs to high-density antigens having the strongest effects. However, since the majority of Ramos cells continued to multiply, it is questionable whether toxicity at this level can provide a significant clinical benefit. Unexpectedly, there was also a population of cells that stained weakly with Annexin V. These cells were distinct from classical apoptotic cells, and appeared to belong to the viable cell population. In these cells, Annexin V stained the region of the Ab cap, in contrast to the ringed staining of classical apoptotic cells. IN
CONCLUSION: 1) Low-level induction of apoptosis was not unique for anti-CD20 Abs, but occurred similarly with other Abs, and 2) results of Annexin V staining experiments may need to be reevaluated. Further studies are required to explain why Annexin V binding sites are exposed in the region of an Ab cap.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409040      PMCID: PMC2902229          DOI: 10.1089/cbr.2008.0567

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  41 in total

Review 1.  Antibody therapy of non-Hodgkin's B-cell lymphoma.

Authors:  Paul Chinn; Gary Braslawsky; Christine White; Nabil Hanna
Journal:  Cancer Immunol Immunother       Date:  2003-02-28       Impact factor: 6.968

2.  Design, construction, and in vitro analyses of multivalent antibodies.

Authors:  Kathy Miller; Gloria Meng; Jun Liu; Amy Hurst; Vanessa Hsei; Wai-Lee Wong; Rene Ekert; David Lawrence; Steven Sherwood; Laura DeForge; Jacques Gaudreault; Gilbert Keller; Mark Sliwkowski; Avi Ashkenazi; Leonard Presta
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

3.  Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells.

Authors:  Rosana B Michel; M Jules Mattes
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

4.  Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.

Authors:  Mark S Cragg; Martin J Glennie
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

Review 5.  A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules.

Authors:  Zoltan A Nagy; Nuala A Mooney
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

6.  CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

Authors:  H T Claude Chan; David Hughes; Ruth R French; Alison L Tutt; Claire A Walshe; Jessica L Teeling; Martin J Glennie; Mark S Cragg
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Authors:  Pina M Cardarelli; Maire Quinn; Dana Buckman; Yu Fang; David Colcher; David J King; Christopher Bebbington; Geoffrey Yarranton
Journal:  Cancer Immunol Immunother       Date:  2001-12-18       Impact factor: 6.968

8.  False leukemia-lymphoma cell lines: an update on over 500 cell lines.

Authors:  H G Drexler; W G Dirks; Y Matsuo; R A F MacLeod
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

Review 9.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

10.  Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.

Authors:  Ali R Jazirehi; Xiao-Hu Gan; Sven De Vos; Christos Emmanouilides; Benjamin Bonavida
Journal:  Mol Cancer Ther       Date:  2003-11       Impact factor: 6.261

View more
  5 in total

1.  Understanding Epstein-Barr Virus Life Cycle with Proteomics: A Temporal Analysis of Ubiquitination During Virus Reactivation.

Authors:  Dong-Wen Lv; Jun Zhong; Kun Zhang; Akhilesh Pandey; Renfeng Li
Journal:  OMICS       Date:  2017-01

2.  Surface levels of CD20 determine anti-CD20 antibodies mediated cell death in vitro.

Authors:  Vijay Singh; Damodar Gupta; Rajesh Arora; Rajendra Prashad Tripathi; Alexandru Almasan; Roger M Macklis
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

Review 3.  Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

Authors:  Niels W C J van de Donk; Maarten L Janmaat; Tuna Mutis; Jeroen J Lammerts van Bueren; Tahamtan Ahmadi; A Kate Sasser; Henk M Lokhorst; Paul W H I Parren
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988

4.  Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response.

Authors:  Vijay Singh; Damodar Gupta; Alexandru Almasan
Journal:  J Cancer Sci Ther       Date:  2015-11-24

5.  Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma.

Authors:  Jacob L Goldberg; Fariba Navid; Jacqueline A Hank; Amy K Erbe; Victor Santana; Jacek Gan; Fenna de Bie; Amal M Javaid; Anna Hoefges; Michael Merdler; Lakeesha Carmichael; KyungMann Kim; Michael W Bishop; Michael M Meager; Steven D Gillies; Janardan P Pandey; Paul M Sondel
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.